Armata Pharma gets USD 3.7 million more in US Department of War funding for AP-SA02 Phase 3 program
A
ARMP• Additional funding for AP-SA02 Phase 3
- Armata received USD 3.7 million in additional non-dilutive funding from the U.S. Department of War for AP-SA02 Phase 3 development.
